AACR 2025 preview – Roche's TIGIT postmortem
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
iTeos, and Roche's RAS mystery, start phase 1
First-in-human study listings include EOS-215 and RO7673396.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
